BMS combo meets in Phase III for malignant pleural mesothelioma Bristol Myers Squibb Co. (NYSE:BMY) said top-line results from the Phase III CheckMate -743 trial showed a combination of anti-PD-1 mAb Opdivo nivolumab and anti-CTLA4...

French biotech Alizé Pharma 3 is taking a more ambitious approach than its predecessors, and now has a €67 million ($74.5 million) series A round to fund two endocrine programs through Phase II testing and...

Express Scripts Holding Co. (NASDAQ:ESRX) posted a list of drugs it will not cover in its 2018 National Preferred Formulary, along with preferred alternatives in each drug category. The new formulary excluded 64 additional drugs...

Radius Health Inc. (NASDAQ:RDUS) gained $1.90 to $44.03 Monday after Express Scripts Holding Co. (NASDAQ:ESRX) listed Radius' osteoporosis drug Tymlos abaloparatide-SC as a preferred alternative to Forteo teriparatide from Eli Lilly and Co. (NYSE:LLY). The...

FDA approved an NDA from Radius Health Inc. (NASDAQ:RDUS) for Tymlos abaloparatide-SC (BA058-SC, ITM-058) to treat postmenopausal women with osteoporosis at high risk for fracture. The company expects to launch the drug in May. EMA...

The European Commission granted conditional approval to Natpar parathyroid hormone from Shire as an adjunct treatment for adults with chronic hypoparathyroidism that cannot be adequately controlled on standard calcium and vitamin D treatment. The company...

Last week’s Nature publication of a hormone secreted by bone that suppresses appetite and can curb weight gain not only adds to the emerging picture of bone as a player in the endocrine system but...

FDA extended by 3 months the PDUFA date for abaloparatide-SC to treat postmenopausal osteoporosis. The new PDUFA date is June 30. Radius said FDA is reviewing information the company submitted in response to the agency’s...

Radius Health Inc. (NASDAQ:RDUS) slipped $2.26 to $40.85 on Friday after it said FDA delayed by three months the PDUFA date for abaloparatide-SC (BA058-SC), which it is reviewing to treat postmenopausal osteoporosis. The new PDUFA...

EMA's CHMP recommended conditional approval of Natpar parathyroid hormone from Shire as an adjunct treatment for adults with chronic hypoparathyroidism that cannot be adequately controlled on standard calcium and vitamin D treatment. To gain full...